Millipore Sigma Vibrant Logo

444289 Marimastat - CAS 154039-60-8 - Calbiochem

Marimastat, CAS 154039-60-8, is a broad-spectrum MMP inhibitor (IC50 = 5, 6, 200, 20, 2, 1.8 & 3.8 nM for MMP-1, -2, -3, -7, -8, -14 and TACE, respectively).

Marimastat - CAS 154039-60-8 - Calbiochem : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: (2S,3R)-N⁴-((1S)-2,2-Dimethyl-1-((methylamino)carbonyl)propyl)-N¹,2-hydroxy-3-(2-methylpropyl)butanediamide, BB-2516

View Products on Sigmaaldrich.com
444289
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
154039-60-8C₁₅H₂₉N₃O₅

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
444289-5MG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Ampoule plast. 5 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewAn orally active peptidyl hydroxamate-based broad-spectrum MMP inhibitor (IC50 in nM = 5, 6, 200, 20, 2, 1.8 and 3.8 for MMP-1, -2, -3, -7, -8, -14 and TACE, respectively) that targets both the substrate binding site and the active-site Zn2+. Marimastate is widely used in studying the involvement of MMPs in various cellular and pathological processes both in vitro and in vivo.
      Catalogue Number444289
      Brand Family Calbiochem®
      Synonyms(2S,3R)-N⁴-((1S)-2,2-Dimethyl-1-((methylamino)carbonyl)propyl)-N¹,2-hydroxy-3-(2-methylpropyl)butanediamide, BB-2516
      References
      ReferencesHansen, H.P., et al. 2002. Int. J. Cancer 98, 210.
      Tsuji, F., et al. 2002. Cytokine 17, 294.
      Barlaam, B., et al. 1999. J. Med. Chem. 42, 4890.
      Whittaker, M., et al. 1999. Chem. Rev. 99, 2735.
      Rasmussen, H.S., and McCann, P.P. 1997. Pharmacol. Ther. 75, 69.
      Product Information
      CAS number154039-60-8
      FormWhite solid
      Hill FormulaC₁₅H₂₉N₃O₅
      Chemical formulaC₁₅H₂₉N₃O₅
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      ApplicationMarimastat, CAS 154039-60-8, is a broad-spectrum MMP inhibitor (IC50 = 5, 6, 200, 20, 2, 1.8 & 3.8 nM for MMP-1, -2, -3, -7, -8, -14 and TACE, respectively).
      Biological Information
      Purity≥98% by NMR
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      S PhraseS: 22-24/25-36/37/39

      Do not breathe dust.
      Avoid contact with skin and eyes.
      Wear suitable protective clothing, gloves and eye/face protection.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      444289-5MG 04055977186062

      Documentation

      Marimastat - CAS 154039-60-8 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Marimastat - CAS 154039-60-8 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      444289

      Références bibliographiques

      Aperçu de la référence bibliographique
      Hansen, H.P., et al. 2002. Int. J. Cancer 98, 210.
      Tsuji, F., et al. 2002. Cytokine 17, 294.
      Barlaam, B., et al. 1999. J. Med. Chem. 42, 4890.
      Whittaker, M., et al. 1999. Chem. Rev. 99, 2735.
      Rasmussen, H.S., and McCann, P.P. 1997. Pharmacol. Ther. 75, 69.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision25-August-2009 RFH
      Synonyms(2S,3R)-N⁴-((1S)-2,2-Dimethyl-1-((methylamino)carbonyl)propyl)-N¹,2-hydroxy-3-(2-methylpropyl)butanediamide, BB-2516
      DescriptionAn orally active peptidyl hydroxamate-based broad-spectrum MMP inhibitor (IC50 in nM = 5, 6, 200, 20, 2, 1.8 and 3.8 for MMP-1, -2, -3, -7, -8, -14 and TACE, respectively) that targets both the substrate binding site and the active-site Zn2+. Marimastate is widely used in studying the involvement of MMPs in various cellular and pathological processes both in vitro and in vivo.
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number154039-60-8
      Chemical formulaC₁₅H₂₉N₃O₅
      Structure formulaStructure formula
      Purity≥98% by NMR
      SolubilityDMSO (15 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesHansen, H.P., et al. 2002. Int. J. Cancer 98, 210.
      Tsuji, F., et al. 2002. Cytokine 17, 294.
      Barlaam, B., et al. 1999. J. Med. Chem. 42, 4890.
      Whittaker, M., et al. 1999. Chem. Rev. 99, 2735.
      Rasmussen, H.S., and McCann, P.P. 1997. Pharmacol. Ther. 75, 69.